Cargando…
OR34-06 Gliclazide Restores Appropriate Glucagon Suppression During OGTT In MODY3 & MODY1 Patients: Results Of The “Glucagon In MODY” Study
Disclosure: I.I. Spiliotis: None. L. Anguelova: None. F. Kavvoura: None. K. Owen: None. Diabetes is a multi-hormone disorder involving both insufficient insulin secretion and aberrant glucagon secretion. MODY (Maturity Onset Diabetes of the Young) is a subgroup of diabetes which is caused by mutatio...
Autores principales: | Spiliotis, Ioannis Ilias, Anguelova, Lia, Kavvoura, Foteini, Owen, Katharine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554237/ http://dx.doi.org/10.1210/jendso/bvad114.1045 |
Ejemplares similares
-
SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY
por: Tyler Broome, David
Publicado: (2023) -
FRI637 Missed MODY With Complex Mutation
por: Bulchandani, Sheetal, et al.
Publicado: (2023) -
PSUN247 Unique Presentation of MODY Type 5
por: Bella, Sama, et al.
Publicado: (2022) -
ODP186 Difficulties in diagnosing MODY: clinical case
por: Volkova, Natalya, et al.
Publicado: (2022) -
SAT082 Utility Of A MODY Probability Calculator As A Systemwide Surveillance Tool
por: Awad, Dana, et al.
Publicado: (2023)